Inhibrx Biosciences (NASDAQ:INBX) Stock Rating Raised to “Sell” at Wall Street Zen

Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) was upgraded by Wall Street Zen from a “strong sell” rating to a “sell” rating in a report issued on Saturday, Wall Street Zen reports.

Other research analysts also recently issued reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inhibrx Biosciences in a report on Friday, September 11th. HC Wainwright dropped their price target on Inhibrx Biosciences from $245.00 to $220.00 and set a “buy” rating for the company in a research note on Monday, November 16th. Finally, Citigroup reissued a “market perform” rating on shares of Inhibrx Biosciences in a report on Friday, September 18th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $185.00.

Read Our Latest Stock Analysis on INBX

Inhibrx Biosciences Trading Down 7.2%

INBX stock opened at $68.97 on Friday. The company has a 50 day simple moving average of $91.17 and a 200 day simple moving average of $92.01. Inhibrx Biosciences has a 1 year low of $57.30 and a 1 year high of $155.29.

Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) last issued its quarterly earnings data on Friday, November 13th. The company reported ($2.46) EPS for the quarter, missing the consensus estimate of ($2.45) by ($0.01). The company had revenue of $2.00 million for the quarter, compared to analyst estimates of $1.90 million. Research analysts forecast that Inhibrx Biosciences will post -9.70 EPS for the current fiscal year.

Insider Transactions at Inhibrx Biosciences

In other news, Director Jon Kayyem acquired 5,000 shares of the stock in a transaction dated Wednesday, September 23rd. The stock was bought at an average price of $100.00 per share, with a total value of $500,000.00. Following the completion of the purchase, the director directly owned 434,360 shares of the company’s stock, valued at $43,436,000. This represents a 1.16% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Kimberly Manhard sold 500 shares of the company’s stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $110.26, for a total value of $55,130.00. Following the completion of the transaction, the director directly owned 8,000 shares of the company’s stock, valued at $882,080. This represents a 5.88% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have bought 62,540 shares of company stock worth $6,347,507 and have sold 1,500 shares worth $168,590. Company insiders own 18.26% of the company’s stock.

Hedge Funds Weigh In On Inhibrx Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ghisallo Capital Management LLC acquired a new position in shares of Inhibrx Biosciences during the third quarter worth $5,004,000. Virtu Financial LLC bought a new stake in shares of Inhibrx Biosciences in the third quarter worth $348,000. Soleus Capital Management L.P. bought a new stake in shares of Inhibrx Biosciences in the third quarter worth $21,017,000. Cetera Investment Advisers bought a new stake in shares of Inhibrx Biosciences in the third quarter worth $338,000. Finally, Jump Financial LLC acquired a new stake in Inhibrx Biosciences in the third quarter valued at $217,000. 82.46% of the stock is currently owned by institutional investors and hedge funds.

About Inhibrx Biosciences

(Get Free Report)

Inhibrx Biosciences, Inc. is a U.S.-based biopharmaceutical company focused on developing biologic medicines for cancer and other serious diseases. Its research uses protein engineering to create investigational therapies designed to engage specific targets in the body. The company’s oncology pipeline has included INBRX-109, an antibody designed to activate the DR5 receptor and studied for chondrosarcoma, and INBRX-106, an investigational OX40-targeting antibody. These candidates are experimental and are not approved medicines.

Further Reading

Analyst Recommendations for Inhibrx Biosciences (NASDAQ:INBX)

Receive News & Ratings for Inhibrx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.